491 related articles for article (PubMed ID: 23008289)
1. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies.
Bottsford-Miller JN; Coleman RL; Sood AK
J Clin Oncol; 2012 Nov; 30(32):4026-34. PubMed ID: 23008289
[TBL] [Abstract][Full Text] [Related]
2. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
3. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
4. Targeting the tumor stroma in cancer therapy.
Anton K; Glod J
Curr Pharm Biotechnol; 2009 Feb; 10(2):185-91. PubMed ID: 19199950
[TBL] [Abstract][Full Text] [Related]
5. [VEGF in neoplastic angiogenesis].
Chekhonin VP; Shein SA; Korchagina AA; Gurina OI
Vestn Ross Akad Med Nauk; 2012; (2):23-33. PubMed ID: 22642175
[TBL] [Abstract][Full Text] [Related]
6. Direct Effects of Anti-Angiogenic Therapies on Tumor Cells: VEGF Signaling.
Simon T; Gagliano T; Giamas G
Trends Mol Med; 2017 Mar; 23(3):282-292. PubMed ID: 28162910
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.
Tie J; Desai J
Crit Rev Oncog; 2012; 17(1):51-67. PubMed ID: 22471664
[TBL] [Abstract][Full Text] [Related]
8. Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies.
Hu-Lowe DD; Chen E; Zhang L; Watson KD; Mancuso P; Lappin P; Wickman G; Chen JH; Wang J; Jiang X; Amundson K; Simon R; Erbersdobler A; Bergqvist S; Feng Z; Swanson TA; Simmons BH; Lippincott J; Casperson GF; Levin WJ; Stampino CG; Shalinsky DR; Ferrara KW; Fiedler W; Bertolini F
Cancer Res; 2011 Feb; 71(4):1362-73. PubMed ID: 21212415
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.
Close A
Future Med Chem; 2016; 8(4):443-62. PubMed ID: 26933926
[TBL] [Abstract][Full Text] [Related]
10. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
[TBL] [Abstract][Full Text] [Related]
11. Response to anti-angiogenesis: an ever changing feature.
Bertolini F
Breast; 2011 Oct; 20 Suppl 3():S61-2. PubMed ID: 22015295
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic therapy in oncology: current status and future directions.
Jayson GC; Kerbel R; Ellis LM; Harris AL
Lancet; 2016 Jul; 388(10043):518-29. PubMed ID: 26853587
[TBL] [Abstract][Full Text] [Related]
13. Anti-Angiogenic Therapy: Current Challenges and Future Perspectives.
Lopes-Coelho F; Martins F; Pereira SA; Serpa J
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33916438
[TBL] [Abstract][Full Text] [Related]
14. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
15. Tumor angiogenesis and vascular normalization: alternative therapeutic targets.
Viallard C; Larrivée B
Angiogenesis; 2017 Nov; 20(4):409-426. PubMed ID: 28660302
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers of response and resistance to antiangiogenic therapy.
Jain RK; Duda DG; Willett CG; Sahani DV; Zhu AX; Loeffler JS; Batchelor TT; Sorensen AG
Nat Rev Clin Oncol; 2009 Jun; 6(6):327-38. PubMed ID: 19483739
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic Effect of Flavonoids and Chalcones: An Update.
Mirossay L; Varinská L; Mojžiš J
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29271940
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.
Pircher A; Jöhrer K; Kocher F; Steiner N; Graziadei I; Heidegger I; Pichler R; Leonhartsberger N; Kremser C; Kern J; Untergasser G; Gunsilius E; Hilbe W
Oncotarget; 2016 Apr; 7(15):20109-23. PubMed ID: 26956051
[TBL] [Abstract][Full Text] [Related]
19. Revisiting tumor angiogenesis: vessel co-option, vessel remodeling, and cancer cell-derived vasculature formation.
Qian CN; Tan MH; Yang JP; Cao Y
Chin J Cancer; 2016 Jan; 35():10. PubMed ID: 26747273
[TBL] [Abstract][Full Text] [Related]
20. Delta-like 4/Notch signaling and its therapeutic implications.
Yan M; Plowman GD
Clin Cancer Res; 2007 Dec; 13(24):7243-6. PubMed ID: 18094402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]